JP2023524997A5 - - Google Patents
Info
- Publication number
- JP2023524997A5 JP2023524997A5 JP2022567343A JP2022567343A JP2023524997A5 JP 2023524997 A5 JP2023524997 A5 JP 2023524997A5 JP 2022567343 A JP2022567343 A JP 2022567343A JP 2022567343 A JP2022567343 A JP 2022567343A JP 2023524997 A5 JP2023524997 A5 JP 2023524997A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020806P | 2020-05-06 | 2020-05-06 | |
| US63/020,806 | 2020-05-06 | ||
| PCT/US2021/030773 WO2021226163A2 (en) | 2020-05-06 | 2021-05-05 | Antibodies targeting clec12a and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524997A JP2023524997A (ja) | 2023-06-14 |
| JPWO2021226163A5 JPWO2021226163A5 (https=) | 2024-05-16 |
| JP2023524997A5 true JP2023524997A5 (https=) | 2024-05-16 |
Family
ID=78468386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567343A Pending JP2023524997A (ja) | 2020-05-06 | 2021-05-05 | Ｃｌｅｃ１２ａを標的とする抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230220084A1 (https=) |
| EP (1) | EP4146704A4 (https=) |
| JP (1) | JP2023524997A (https=) |
| KR (1) | KR20230008157A (https=) |
| CN (1) | CN115697402A (https=) |
| AU (1) | AU2021267023A1 (https=) |
| BR (1) | BR112022022418A2 (https=) |
| CA (1) | CA3177818A1 (https=) |
| IL (1) | IL297950A (https=) |
| MX (1) | MX2022013882A (https=) |
| WO (1) | WO2021226163A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| EP4291233A4 (en) * | 2021-02-10 | 2025-05-21 | Wugen, Inc. | POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF DISEASES |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| GB202214132D0 (en) * | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009523460A (ja) * | 2006-01-24 | 2009-06-25 | ドマンティス リミテッド | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
| WO2008127735A1 (en) * | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| EP3470431A1 (en) * | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| EP3310378B1 (en) * | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| WO2017011342A1 (en) * | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| AU2017330346C1 (en) * | 2016-09-21 | 2025-03-06 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
| SG11202002298PA (en) * | 2017-09-14 | 2020-04-29 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1) |
| US12097219B2 (en) * | 2018-09-10 | 2024-09-24 | Legend Biotech Ireland Limited | Single-domain antibodies against CLL1 and constructs thereof |
-
2021
- 2021-05-05 KR KR1020227042237A patent/KR20230008157A/ko active Pending
- 2021-05-05 CA CA3177818A patent/CA3177818A1/en active Pending
- 2021-05-05 JP JP2022567343A patent/JP2023524997A/ja active Pending
- 2021-05-05 CN CN202180033626.0A patent/CN115697402A/zh active Pending
- 2021-05-05 BR BR112022022418A patent/BR112022022418A2/pt unknown
- 2021-05-05 MX MX2022013882A patent/MX2022013882A/es unknown
- 2021-05-05 US US17/923,411 patent/US20230220084A1/en active Pending
- 2021-05-05 WO PCT/US2021/030773 patent/WO2021226163A2/en not_active Ceased
- 2021-05-05 AU AU2021267023A patent/AU2021267023A1/en not_active Abandoned
- 2021-05-05 EP EP21799694.1A patent/EP4146704A4/en active Pending
- 2021-05-05 IL IL297950A patent/IL297950A/en unknown